Logo image of HSDT

HELIUS MEDICAL TECHNOLOGIES (HSDT) Stock Fundamental Analysis

NASDAQ:HSDT - Nasdaq - US42328V8019 - Common Stock - Currency: USD

0.538  0 (-0.19%)

After market: 0.538 0 (0%)

Fundamental Rating

3

HSDT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 190 industry peers in the Health Care Equipment & Supplies industry. While HSDT seems to be doing ok healthwise, there are quite some concerns on its profitability. HSDT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year HSDT has reported negative net income.
In the past 5 years HSDT always reported negative net income.
In the past 5 years HSDT always reported negative operating cash flow.
HSDT Yearly Net Income VS EBIT VS OCF VS FCFHSDT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

HSDT has a worse Return On Assets (-158.62%) than 90.96% of its industry peers.
HSDT has a worse Return On Equity (-233.19%) than 79.26% of its industry peers.
Industry RankSector Rank
ROA -158.62%
ROE -233.19%
ROIC N/A
ROA(3y)-108.35%
ROA(5y)-127.05%
ROE(3y)-236.75%
ROE(5y)-248.57%
ROIC(3y)N/A
ROIC(5y)N/A
HSDT Yearly ROA, ROE, ROICHSDT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20K -20K

1.3 Margins

HSDT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HSDT Yearly Profit, Operating, Gross MarginsHSDT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K

More info and screens

6

2. Health

2.1 Basic Checks

HSDT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HSDT has more shares outstanding
The number of shares outstanding for HSDT has been increased compared to 5 years ago.
HSDT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
HSDT Yearly Shares OutstandingHSDT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K
HSDT Yearly Total Debt VS Total AssetsHSDT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M

2.2 Solvency

HSDT has an Altman-Z score of -48.13. This is a bad value and indicates that HSDT is not financially healthy and even has some risk of bankruptcy.
HSDT has a Altman-Z score of -48.13. This is amonst the worse of the industry: HSDT underperforms 90.43% of its industry peers.
HSDT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -48.13
ROIC/WACCN/A
WACC9.14%
HSDT Yearly LT Debt VS Equity VS FCFHSDT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 3.61 indicates that HSDT has no problem at all paying its short term obligations.
HSDT has a better Current ratio (3.61) than 64.89% of its industry peers.
A Quick Ratio of 3.10 indicates that HSDT has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.10, HSDT is in the better half of the industry, outperforming 66.49% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.61
Quick Ratio 3.1
HSDT Yearly Current Assets VS Current LiabilitesHSDT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 71.24% over the past year.
Looking at the last year, HSDT shows a very negative growth in Revenue. The Revenue has decreased by -18.17% in the last year.
HSDT shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.05% yearly.
EPS 1Y (TTM)71.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.97%
Revenue 1Y (TTM)-18.17%
Revenue growth 3Y-0.81%
Revenue growth 5Y6.05%
Sales Q2Q%-64.34%

3.2 Future

Based on estimates for the next years, HSDT will show a very strong growth in Earnings Per Share. The EPS will grow by 22.52% on average per year.
The Revenue is expected to grow by 142.98% on average over the next years. This is a very strong growth
EPS Next Y60.22%
EPS Next 2Y35.04%
EPS Next 3Y22.52%
EPS Next 5YN/A
Revenue Next Year-38.12%
Revenue Next 2Y-17.88%
Revenue Next 3Y5.69%
Revenue Next 5Y142.98%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
HSDT Yearly Revenue VS EstimatesHSDT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M 80M
HSDT Yearly EPS VS EstimatesHSDT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -500 -1K -1.5K -2K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

HSDT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HSDT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HSDT Price Earnings VS Forward Price EarningsHSDT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HSDT Per share dataHSDT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

HSDT's earnings are expected to grow with 22.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.04%
EPS Next 3Y22.52%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HSDT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HELIUS MEDICAL TECHNOLOGIES

NASDAQ:HSDT (2/21/2025, 8:26:04 PM)

After market: 0.538 0 (0%)

0.538

0 (-0.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-11 2024-11-11/amc
Earnings (Next)03-26 2025-03-26/amc
Inst Owners6.74%
Inst Owner Change118.9%
Ins Owners0.24%
Ins Owner Change0%
Market Cap2.01M
Analysts43.33
Price Target4.08 (658.36%)
Short Float %1.58%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.53%
Min EPS beat(2)-25.49%
Max EPS beat(2)8.44%
EPS beat(4)3
Avg EPS beat(4)16.68%
Min EPS beat(4)-25.49%
Max EPS beat(4)61.81%
EPS beat(8)6
Avg EPS beat(8)14.77%
EPS beat(12)9
Avg EPS beat(12)17.4%
EPS beat(16)10
Avg EPS beat(16)-20.84%
Revenue beat(2)1
Avg Revenue beat(2)-23.86%
Min Revenue beat(2)-66.67%
Max Revenue beat(2)18.95%
Revenue beat(4)2
Avg Revenue beat(4)-23.24%
Min Revenue beat(4)-66.67%
Max Revenue beat(4)18.95%
Revenue beat(8)4
Avg Revenue beat(8)-21.74%
Revenue beat(12)7
Avg Revenue beat(12)-4.4%
Revenue beat(16)8
Avg Revenue beat(16)-3.81%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.17%
EPS NY rev (1m)0%
EPS NY rev (3m)0.35%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-62.69%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-36.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4
P/FCF N/A
P/OCF N/A
P/B 0.53
P/tB 0.53
EV/EBITDA N/A
EPS(TTM)-6.18
EYN/A
EPS(NY)-2.55
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.13
BVpS1.02
TBVpS1.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -158.62%
ROE -233.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-108.35%
ROA(5y)-127.05%
ROE(3y)-236.75%
ROE(5y)-248.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.61
Quick Ratio 3.1
Altman-Z -48.13
F-ScoreN/A
WACC9.14%
ROIC/WACCN/A
Cap/Depr(3y)14.64%
Cap/Depr(5y)48.54%
Cap/Sales(3y)6.07%
Cap/Sales(5y)10.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.97%
EPS Next Y60.22%
EPS Next 2Y35.04%
EPS Next 3Y22.52%
EPS Next 5YN/A
Revenue 1Y (TTM)-18.17%
Revenue growth 3Y-0.81%
Revenue growth 5Y6.05%
Sales Q2Q%-64.34%
Revenue Next Year-38.12%
Revenue Next 2Y-17.88%
Revenue Next 3Y5.69%
Revenue Next 5Y142.98%
EBIT growth 1Y16.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y27.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.21%
OCF growth 3YN/A
OCF growth 5YN/A